C3 and autoimmune disease: There are currently several clinical trials underway using C3 inhibitors (e.g., AMY-101 and APL-2) and TLR 7/8/9 antagonists (e.g., IMO-8400) for various inflammatory and autoimmune diseases (24–26), indicating that these drugs may be readily incorporated into DMD gene therapy clinical trials.